(Q48467310)

11 February 2018

title

Temozolomide treatment for newly diagnosed anaplastic oligodendrogliomas: a clinical efficacy trial (English)

1 reference

11 February 2018

1 reference

0 references

A Taliansky-Aronov

1

1 reference

11 February 2018

F Bokstein

series ordinal

2

1 reference

11 February 2018

I Lavon

series ordinal

3

1 reference

11 February 2018

T Siegal

series ordinal

4

1 reference

11 February 2018

publication date

20 July 2006

1 reference

11 February 2018

Journal of Neuro-Oncology

published in

1 reference

11 February 2018

volume

79

1 reference

11 February 2018

issue

2

1 reference

11 February 2018

page(s)

153-157

1 reference

11 February 2018

https://scigraph.springernature.com/pub.10.1007/s11060-005-9020-1

exact match

0 references

cites work

Response rate and prognostic factors of recurrent oligodendroglioma treated with procarbazine, CCNU, and vincristine chemotherapy. Dutch Neuro-oncology Group.

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11060-005-9020-1

Long-term outcome of oligodendrogliomas

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11060-005-9020-1

Chemotherapy of anaplastic oligodendroglial tumours

21 January 2018

1 reference

12 December 2020

High-dose chemotherapy with stem cell rescue as initial therapy for anaplastic oligodendroglioma.

1 reference

12 December 2020

Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy.

1 reference

12 December 2020

Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group

1 reference

12 December 2020

Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971.

1 reference

12 December 2020

Aggressive oligodendroglioma: a chemosensitive tumor

1 reference

12 December 2020

Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972.

1 reference

12 December 2020

Diagnosis and management of oligodendroglioma

1 reference

12 December 2020

Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group

1 reference

12 December 2020

10.1007/S11060-005-9020-1

Identifiers

DOI

1 reference

11 February 2018

1 reference

11 February 2018